NIEHS procures Provantis preclinical software solution for National Toxicology Program studies

Instem, a leading provider of early drug development software solutions, announced today that the National Institute of Environmental Health Sciences (NIEHS) has purchased the Provantis® preclinical software solution to support the collection, management and maintenance of the reproductive, perinatal and developmental National Toxicology Program (NTP) studies. These studies are done predominantly at contractor laboratories at various sites throughout the United States.

The value of the award to Instem, funded completely by the federal government, is $656,100.

Managed by NIEHS, the NTP is an interagency program whose mission is to evaluate agents of public health concern by developing and applying tools of modern toxicology and molecular biology. The program maintains an objective, science-based approach in dealing with critical issues in toxicology and is committed to using the best science available to prioritize, design, conduct, and interpret its studies.

The NIEHS will be using Instem's SaaS (Software-as-a-Service) model offering simpler, more cost effective ways to provide software functionality, maintenance, and support over the Internet. Since 2005, Instem has utilized a state-of-the-art data center, which is being used by clients running GLP and non-GLP studies.

Part of the integrated Provantis solution suite, this module will support the NTP reproductive toxicologist or teratologist in conducting all study types, including ICH protocols, multigeneration, developmental toxicity, behavioral and development neurotoxicity studies. Particularly flexible in its design, Instem's solution supports a full range of data entry types, simplifies the management of event driven studies while enabling NTP program users to generate simple and complex custom reports.

Source:

 Instem

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients